Target Gene/Pathway（薬物標的遺伝子／パスウェイリスト）💬 Info on mouse-over

No.	KEGG PATHWAY On map, Yellow: Drug target, Red: All disease-related	KEGG GENES	KEGG DRUG	DrugBank	指定難病告示番号
1	Adipocytokine signaling pathway 💬	1件: JAK2 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
2	AGE-RAGE signaling pathway in diabetic complications 💬	1件: JAK2 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
3	Chemokine signaling pathway 💬	1件: JAK2 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
4	Cholinergic synapse 💬	1件: JAK2 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
5	Coronavirus disease - COVID-19 💬	1件: JAK1 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
6	EGFR tyrosine kinase inhibitor resistance 💬	2件: JAK1, JAK2 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
7	Epstein-Barr virus infection 💬	1件: JAK1 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
8	Growth hormone synthesis, secretion and action 💬	1件: JAK2 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
9	Hepatitis B 💬	2件: JAK1, JAK2 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
10	Hepatitis C 💬	1件: JAK1 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
11	Herpes simplex virus 1 infection 💬	2件: JAK1, JAK2 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
12	Human cytomegalovirus infection 💬	1件: JAK1 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
13	Human papillomavirus infection 💬	1件: JAK1 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
14	Human T-cell leukemia virus 1 infection 💬	1件: JAK1 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
15	Influenza A 💬	2件: JAK1, JAK2 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
16	JAK-STAT signaling pathway 💬	2件: JAK1, JAK2 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
17	Kaposi sarcoma-associated herpesvirus infection 💬	2件: JAK1, JAK2 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
18	Leishmaniasis 💬	2件: JAK1, JAK2 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
19	Measles 💬	1件: JAK1 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
20	Necroptosis 💬	2件: JAK1, JAK2 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
21	NOD-like receptor signaling pathway 💬	1件: JAK1 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
22	Osteoclast differentiation 💬	1件: JAK1 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
23	Pancreatic cancer 💬	1件: JAK1 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
24	Pathways in cancer 💬	2件: JAK1, JAK2 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
25	PD-L1 expression and PD-1 checkpoint pathway in cancer 💬	2件: JAK1, JAK2 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
26	PI3K-Akt signaling pathway 💬	2件: JAK1, JAK2 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
27	Prolactin signaling pathway 💬	1件: JAK2 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
28	Signaling pathways regulating pluripotency of stem cells 💬	2件: JAK1, JAK2 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
29	Th1 and Th2 cell differentiation 💬	2件: JAK1, JAK2 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
30	Th17 cell differentiation 💬	2件: JAK1, JAK2 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
31	Toxoplasmosis 💬	2件: JAK1, JAK2 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
32	Tuberculosis 💬	2件: JAK1, JAK2 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
33	Viral carcinogenesis 💬	1件: JAK1 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬

先頭へ